Semaglutide has the most menopause-specific evidence, and it is limited. A 2026 Spanish Menopause Society statement called it largely observational; tirzepatide needs menopause-specific study.1
Hormone therapy and GLP-1 weight loss: women on hormone therapy lost more weight on semaglutide in one retrospective cohort, but the statement calls the link hypothesis-generating and not a reason to start hormone therapy.21
Protect muscle and bone. Protein, resistance exercise and fracture risk belong in the plan.14
Two peptides are approved for postmenopausal osteoporosis: teriparatide and abaloparatide.56
On this page
- GLP-1 drugs after menopause
- The hormone-therapy question
- Muscle, protein and sleep
- The bone-building peptides
- Where the evidence is thin
- Frequently asked questions
- Related on Grey Peptides
- Sources
GLP-1 drugs after menopause
A 2026 position statement from the Spanish Menopause Society reviewed the literature to April 2026 and concluded that semaglutide has the most direct menopause-specific evidence among incretin drugs, but that it remains limited and largely observational. Tirzepatide and other dual-incretin drugs are promising, particularly for cardiometabolic disease and sleep apnoea, but need menopause-specific evaluation.1
One small study compared women before and after menopause over four months on the same semaglutide regimen: postmenopausal women started heavier, but their weight loss (5.9 kg against 4.5 kg) and fat loss were similar to the premenopausal group's.3 Small, short and not randomized (our reasoning, from its design).
The hormone-therapy question
In a retrospective Mayo Clinic cohort of postmenopausal women on semaglutide for overweight or obesity, the 16 women using menopausal hormone therapy lost more weight than the 90 who were not: 16% against 12% of body weight at 12 months, and the difference held after adjusting for confounders. The authors called for larger studies.2
The Spanish Menopause Society statement read this association as hypothesis-generating and said it should not justify starting hormone therapy solely to increase weight loss.1 A separate 2026 review raises a different interaction: tirzepatide slows stomach emptying and may alter the absorption of oral progestogens, including those used to protect the womb lining during hormone therapy, a possibility it calls biologically plausible but unproven.7 Women on oral hormone therapy who start tirzepatide may want to raise it with the prescriber (our reasoning). The contraception page covers the same mechanism for the pill.
Muscle, protein and sleep
Weight lost on a GLP-1 drug includes some lean mass, and postmenopausal women already lose lean mass and face higher sarcopenia risk. A 2026 review notes that a fall in lean body mass is not necessarily a meaningful loss of muscle function, and that adequate protein and resistance exercise may help preserve it, though the evidence in semaglutide-treated postmenopausal women is indirect.4 The menopause statement likewise puts visceral fat, skeletal muscle, fracture risk, resistance exercise and protein into its framework for using these drugs.1 Our Starting a GLP-1 hub covers the lean-mass trials in more depth.
The bone-building peptides
Two peptide drugs are FDA-approved to treat postmenopausal osteoporosis. Their labels, quoted word for word:
From the FDA label (quoted word for word from the current US label)
| Product | What the label says | Label section |
|---|---|---|
| Forteo (teriparatide) | “For the treatment of postmenopausal women with osteoporosis at high risk for fracture” | section 15 |
| Forteo (teriparatide) | “In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures.” | section 15 |
| Tymlos (abaloparatide) | “Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.” | section 16 |
| Tymlos (abaloparatide) | “TYMLOS is not indicated for use in females of reproductive potential.” | section 8.16 |
Teriparatide also carries indications for men with osteoporosis;5 abaloparatide is, in its label's words, a human parathyroid hormone related peptide analog.6 Both are prescription drugs with their own label warnings; our bone-building peptides guide covers them in depth.
Where the evidence is thin
Bremelanotide (PT-141) is approved for low sexual desire only before menopause; use afterwards is outside its label.8 The peptides most heavily marketed to menopausal women for energy, recovery or "anti-ageing" have, as far as we found, no trials in menopausal women at all. Our women's health hub and the menopause review list what we searched and what turned up.
Frequently asked questions
Does hormone therapy make semaglutide work better?
One retrospective cohort found more weight loss in women on hormone therapy, but it was small, and a 2026 expert statement called the association hypothesis-generating and not a reason to start hormone therapy for weight loss.
Which peptides are approved for osteoporosis after menopause?
Teriparatide (Forteo) and abaloparatide (Tymlos), both for postmenopausal women with osteoporosis at high risk for fracture, per their labels.
Related on Grey Peptides
Sources
Studies are cited by PMID and checked on PubMed; labels by their DailyMed set and version and quoted from the cached text. All read November 3, 2026.
- Sanchez-Prieto M, Romero-Dominguez M, Orozco R, et al. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas 2026;213:109101. PMID 42664617. Source
- Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause 2024;31(4):266-274. PMID 38446869. Source
- Nicolau J, Blanco-Anesto J, Bonet A, et al. Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause. Metab Syndr Relat Disord 2025;23(1):70-76. PMID 39761057. Source
- Pereira NRM, Ishikura IA, Tufik S, Hachul H. Semaglutide in postmenopausal women: Clinical implications for weight loss, muscle health, and sleep-disordered breathing. Maturitas 2026;214:109129. PMID 42772087. Source
- Forteo (teriparatide) US prescribing information (Eli Lilly; DailyMed set aae667c5, version 44, effective August 3, 2026), sections 7, 8 and 12. DailyMed
- Tymlos (abaloparatide) US prescribing information (Radius Health; DailyMed set 712143d9, version 19, effective August 11, 2026), sections 7, 8 and 12. DailyMed
- Viana DPDC, Invitti AL, Jacobsen L, Schor E. Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy. Maturitas 2026;214:109116. PMID 42721915. Source
- Vyleesi (bremelanotide) US prescribing information (Cosette Pharmaceuticals; DailyMed set f1d0c1b5, version 1, effective November 13, 2025), sections 7, 8 and 12. DailyMed
This section reports what labels, LactMed and published studies say; it is not medical advice, and it does not replace the obstetrician, midwife, prescriber or pharmacist who knows your history. Grey Peptides sells nothing, links to no seller and rates none. If you are pregnant and have taken something you are unsure of, the MotherToBaby service (1-866-626-6847 in the US) answers questions about exposures in pregnancy and breastfeeding.